1148results about How to "Achieve therapeutic effect" patented technology

The invention relates to a heptamethine indocyanine dye containing N-fatty esters or N-fatty amide side chains, a synthetic method thereof and applications thereof in tumor targeting imaging and treatment. The heptamethine indocyanine dye which possesses or individually possesses near infrared absorption, fluorography and antineoplastic activity allows present research and development ideas and treatment levels of tumor targeting treatment medicaments to be greatly improved, and has great significances to aspects of early discovery, control and the like of various tumors.

The invention relates to a photosensitive PRP (platelet-rich plasma) gel and a preparation method and application thereof. The preparation method comprises the following steps of mixing a biocompatible medium solution of a macromolecule modified by an o-nitrobenzyl photo response group and an extracted PRP according to a certain ratio, so as to form a gel precursor solution; then, radiating the gel precursor solution by light, and enabling the o-nitrobenzyl group in the macromolecule modified by the o-nitrobenzyl photo response group to generate photochemical reaction under the excitation action of a light source, so as to produce an aldehyde functional group; generating coupling reaction with amino distributed at the surface of the protein in the PRP to form an imine bond, so as to realize the preparation of the photosensitive PRP gel. Compared with the prior art, the photosensitive PRP gel prepared by the method has the advantages that the internal cell factors can be slowly released, and the tight and seamless bonding between the PRP gel and wounds is realized.

The invention relates to the technical field of medicine, which is a preparation of a taxane drug for intravenous drug delivery, consisting of two parts of drug solution and an emulsion. The drug solution is composed of paclitaxel or docetaxel, a pH regulator and a solvent for injection, wherein, the solvent for injection is an organic solvent; the emulsion comprises a fat emulsion and is composed of oil for injection, an emulsifier, an antioxidant, an isotonic regulator, a stabilizer, a pH regulator and water for injection. When in use, the drug solution can be added and evenly mixed in the emulsion for direct intravenous drip according to the clinical drug dosage and can also be firstly added in the emulsion with the volume that is not less than 5 times of the volume of the drug solution according to the clinical drug dosage and then added with a certain amount of physiological saline or glucose injection for intravenous drip. The preparation of the invention does not contain solubilizer and has the advantages of little toxicity, safety, effectivity, stability and economy. The fat emulsion can also be taken as a nutrition replenisher for a patient, thus achieving better treatment effects. The physiological saline or the glucose injection can also replace a certain amount of the emulsion, so the storage and the transportation are convenient, and the preparation is more economical.

The invention discloses a cancer pain-relieving plaster prepared by a preparation A and a preparation B, wherein the preparation A is prepared by five branches, five skins, one brick, one stone, five cores, and the like; the preparation B is prepared by poria cocos, pinellia ternate, jackinthepulpit tuber rhizome, trichosanthes kirilowii maxim, centipede, zaocys dhumnade, and the like. When the cancer pain-relieving plaster is prepared, the preparation B is added into the preparation A to be decocted for 4.5-5.5 hours, red lead is added to be mixed to pasty fluid, then cold water is added for steeping to releasing fire-toxin, water is changed once one day, and the plaster is obtained after steeping for 7 days. When the plaster is used, the plaster is coated on cotton cloth or plaster paster. The cancer pain-relieving plaster mainly aims at tumour cancers of lung cancer, gastric cancer, liver cancer, pancreatic cancer, colon caner, rectal caner, kidney cancer, bladder caner, breast cancer, cervical cancer, ovarian cancer, esophagus cancer, laryngeal cancer, and the like and is obvious in pain-relieving effect.

The invention discloses a composite nano-drug for integrated tumor diagnosis and treatment and a preparation method thereof. A chemotherapeutic drug, a photodynamic drug and shRNA plasmids capable of reversing multidrug-resistant MDR1 genes of tumor cells are located through a nano-carrier, a magnetic nano-sphere with precious metal nano-particles arranged on the surface serves as a kernel of the nano-carrier, mesoporous silica with the surface modified with amino groups serves as a shell of the nano-carrier, and a polyelectrolyte thin film layer structure with pH response is formed on the surface of the kernel-shell structure through a layer-by-layer self-assembly technology. The composite nano-drug integrates targeted drug delivery, multimode imaging, chemotherapy, photodynamic therapy and gene therapy, can be applied to early diagnosis of tumors, image mediation and real-time monitoring treatment at the same time and overcomes the defect that tumor diagnosis and treatment are separate in the prior art; besides, the composite nano-drug is simple in preparation process, high in operability and suitable for industrial production.

The invention discloses a magnetic resonance imaging nanometer drug carrier, and a nanometer drug loading system and a preparation method thereof. The magnetic resonance imaging nanometer drug carrieris a triblock polymer nanoparticle, wherein the triblock polymer is PLGA-PEI-PEG, and has active groups on the surface, and the active groups comprise amino, hydroxyl and carboxyl. According to the present invention, the drug carrier can efficiently load a nuclear magnetic resonance imaging drug and an antitumor drug to make the antitumor drug specifically reach the tumor lesion site, such that the nuclear magnetic resonance positioning of the superparamagnetic ferroferric oxide nanoparticle at the tumor region can be achieved while the high-selectivity and low-toxicity treatment effect can be achieved, and the disadvantages of poor selectivity, strong toxic-side effect, easy drug-resistance generation and the like of the traditional cytotoxic drugs can be overcome; and the preparation method is simple and is easy to perform, the prepared triblock polymer nanoparticle can be stably stored in the aqueous solution so as to be easily stored, and various functional groups exist on the surface of the particle, such that the prepared triblock polymer nanoparticle can be easily subjected to surface modification or surface functionalization.

The invention provides a method and device for building diagnosis inquiring channels. The method includes the steps of receiving diagnosis inquiring questions input by patients through preset communication tools, decomposing diagnosis inquiring keywords in the diagnosis inquiring questions, finding diagnosis inquiring doctors matched with the diagnosis inquiring keywords, obtaining contact information of communication tools of the diagnosis inquiring doctors, and building the diagnosis inquiring channels between the doctors and the patients through the communication tools according to the contact information. The diagnosis inquiring keywords in the diagnosis inquiring questions asked by the patients are decomposed with the data extracting technology, the diagnosis inquiring doctors matched with the diagnosis inquiring keywords are found with the data retrieval technology, the diagnosis inquiring channels between the patients and the diagnosis inquiring doctors are rapidly built in time, the patients do not need to have medical science knowledge and also do not need to wait for registration for a long time, the diagnosis inquiring doctors can be automatically distributed for the patients only through simple disease descriptions, the patients can be in communication with the diagnosis inquiring doctors through the communication tools in time, and primary diagnosis and treatment on diseases can be achieved.

The invention provides a composite nano-grade novel material based on cancer early-stage integrated detection, diagnoses, and treatment, and a preparation method thereof. According to the invention, gold nano-cage (gold nano-box) and nano-grade iron oxide are assembled, such that gold nano-cage (box)/nano-grade iron oxide composite particles are synthesized. With an assembling method from the inside to the outside, the gold nano-cage (box) is first prepared; iron oxide is nucleated and grown in the gold nano-cage (box); with a surfactant (such as glucan or the like), mono-dispersed iron oxide is obtained; the iron oxide is packaged by using biological molecules, such that the gold nano-cage (box)/nano-grade iron oxide composite particles are obtained; surface modification is carried out by using biological targeting molecules (antibodies or DNA molecules). The material is used in tumor magnetic resonance imaging, fluorescence imaging, dark field imaging, specific targeting multifunctional diagnosis, and photothermal therapy. The material can also be used as a targeting medicine carrier.

The present invention provides methods of preventing, treating, managing or ameliorating disorders utilizing an integrin α_vβ₃ antagonist in combination with an HMG-CoA reductase inhibitor and/or a bisphosphonate. The present invention also encompasses methods of preventing, treating, managing or ameliorating disorders utilizing an integrin α_vβ₃ antagonist in combination with an HMG-CoA reductase inhibitor and/or a bisphophonate, in further combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an integrin α_vβ₃ antagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. In particular, the present invention provides methods of preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of integrin α_vβ₃, disorders associated with abnormal bone metabolism, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith, utilizing an antibody that immunospecifically binds to integrin α_vβ₃ (e.g., VITAXIN®) in combination with an HMG-CoA reductase inhibitor and/or bisphosphonate, and optionally in combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an integrin α_vβ₃ antagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. The present also invention encompasses compositions and articles of manufacture for use in preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of integrin α_vβ₃, disorders associated with abnormal bone metabolism, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith.

The invention discloses an Endoglin antibody coupled liposome as well as a preparation method and an application thereof, and relates to an Endoglin antibody coupled liposome. The Endoglin antibody coupled liposome comprises nano liposome particles, Endoglin antibody molecules, a coupling agent and a plasmid DNA (deoxyribonucleic acid) /antineoplastic drug/imaging material, wherein the coupling agent is used for coupling the Endoglin antibody onto the nano liposome particles, and the plasmid DNA/antineoplastic drug/imaging material is carried by the nano liposome particles. The preparation method comprises the following steps: preparing a PEG (polyethylene glycol)-modified phospholipid lamina, filling the plasmid/drug/imaging material to prepare the nano liposome particles, homogenizing and purifying the nano liposome particles, thiolating the Endoglin antibody, and coupling the Endoglin antibody molecules on the PEG-modified nano liposome. The Endoglin antibody coupled liposome can be used for preparing drugs for diagnosing and treating solid tumors.

The invention relates to copper selenide/mesoporous silica core-shell nanoparticles and a preparation method and application thereof. The copper selenide/mesoporous silica core-shell nanoparticles are Cu2<-x>Se/mSiO2-PEG core-shell nanoparticles, where x is 0-1, and m is mesoporous. The preparation method comprises the following steps: preparing a Cu2<-x>Se nanocrystalline, transferring the hydrophobic Cu2<-x>Se nanocrystalline into an aqueous phase through CTAB (Cetyltrimethyl Ammonium Bromide), and growing a mesoporous silica layer on the surface of the CTAB through a sol-gel method by taking the CTAB as a template; and finally, modifying and coupling polyethylene glycol to the surface, and obtaining the copper selenide/mesoporous silica core-shell nanoparticles. The invention also discloses application in preparation of diagnosis and treatment preparations. The obtained Cu2<-x>Se/mSiO2-PEG has extremely low cytotoxicity, so that cancer cells can be effectively killed through light and heat, and the anti-cancer drug DOX can be effectively transmitted into the cells and has pH and laser-sensitive drug sustained release performance, so that a synergistic effect between photothermal therapy and chemotherapy can be realized.

The present invention provides a new type balloon dilation catheter which includes ballon and medication material coated on stent. Said medication material comes from one or two and more than two mixtures of heparin sodium, fiber degrading enzyme, serine proteinase, batroxobin, aspirin, genistein, hirudin and its recombined product, colchicine, sirolimus, biolimus, zotarolimus, tracrolimus, pimecrolimus, simvastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, daunomycin, mitomycin C, actinomycin D, taxol, celastrol, methopterin, 5-fluorouracil, cytarabine and 6-purinethol. The balloon is made of macromolecule nylon material, and the stimulation to blood vessel is far lower than the stent with metal structure.

The invention discloses a tumor targeting metal complex, a synthetic method and application. The synthetic method comprises the steps of connecting a ligand with a substituent group and a targeting molecule, complexing the ligand and metal ions, and synthesizing to obtain the tumor targeting metal complex, wherein the ligand is one of a phenanthroline derivative, a dipyridyl derivative, a benzimidazole derivative, a phenyl-pyridine derivative and a thiophene-pyridine derivative; the targeting molecule is one of biotin, folic acid, integrin, transferrin, cell-penetrating peptide, octa-poly-L-arginine, MUC-1 attached membrane protein, galactosamine, neovascular targeting peptide and a granulocyte-macrophage colony-stimulating factor; the metal ions are ruthenium, osmium, rhodium or iridium ions. The complex obtained by the method provided by the invention can be selectively absorbed by tumor cells, and induces apoptosis of the tumor cells. In a nude mouse tumor-bearing model, the tumor targeting metal complex can image and treat tumors, and the toxicity of organs and tissues is reduced.